Lilly completes biopharma acquisitions
Lilly expands its portfolio of treatments for cardiometabolic diseases with acquisition of Versanis Bio and Sigilon Therapeutics.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
